High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection.
about
Cytomegalovirus-induced immunopathology and its clinical consequencesCMV in Hematopoietic Stem Cell TransplantationCytomegalovirus infection in the bone marrow transplant patientHow I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipientsRisk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control studyGuidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspectiveCytomegalovirus infection as a cause of cytopenia after chemotherapy for hematological malignancies.Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience.Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy.Surveillance of active human cytomegalovirus infection in hematopoietic stem cell transplantation (HLA sibling identical donor): search for optimal cutoff value by real-time PCR.Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation.Quantitative temporal viromics: an approach to investigate host-pathogen interactionThe clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches.Outcomes and prognostic factors of non-HIV patients with pneumocystis jirovecii pneumonia and pulmonary CMV co-infection: A Retrospective Cohort Study.Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects.Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.Persistent neutrophilic meningitis in an immunocompetent patient after basilar skull fracture: case report.Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipientsPrevention of cytomegalovirus disease in recipients of allogeneic stem cell transplantsCytomegalovirus viral load and virus-specific immune reconstitution after peripheral blood stem cell versus bone marrow transplantationRisk of cytomegalovirus transmission by blood products to immunocompromised patients and means for reduction.The Impact of Opportunistic Infections on Clinical Outcome and Healthcare Resource Uses for Adult T Cell Leukaemia.Cytomegalovirus infection according to cell source after hematopoietic cell transplantation in pediatric patientsCytomegalovirus in hematopoietic stem cell transplant recipientsReduced Mortality of Cytomegalovirus Pneumonia After Hematopoietic Cell Transplantation Due to Antiviral Therapy and Changes in Transplantation PracticesPriorities for CMV vaccine developmentEfficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation.Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer?Acceleration of allograft failure by cytomegalovirusCMV Serostatus of Donor-Recipient Pairs Influences the Risk of CMV Infection/Reactivation in HSCT Patients.Timeline, epidemiology, and risk factors for bacterial, fungal, and viral infections in children and adolescents after allogeneic hematopoietic stem cell transplantation.Efficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipientsImpact of pretransplant donor and recipient cytomegalovirus serostatus on outcome for multiple myeloma patients undergoing reduced intensity conditioning allogeneic stem cell transplantation.Utility of the Enzyme-Linked Immunospot Interferon-γ-Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients.Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis.Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study.Immunobiology of human cytomegalovirus: from bench to bedside.Generation of potent neutralizing human monoclonal antibodies against cytomegalovirus infection from immune B cells.Cytomegalovirus pneumonia in hematopoietic stem cell recipients.Human dendritic cells and transplant outcome.
P2860
Q21195897-78B6A388-9EB4-4D33-A54B-2DA601B33C89Q26740385-5F749281-C381-4C86-8514-60F63797AADAQ26771385-84060E79-A8E2-4A70-BD0E-025711AE55FCQ28069489-A113D89D-5086-42F3-BB62-FE019B06A917Q28298477-0C9EBFD5-4000-433B-BD0D-4C7A283FA1ECQ28388806-5223ABF1-6280-4818-82FB-67C35647AD10Q33401951-984C1C32-8543-412C-BFF6-E7BC567C2CB8Q33566426-2920CFE6-2A42-4EFE-81F0-7EEC84F31D4BQ33576882-2B0E9E75-207C-4E0F-8F73-8562034354F9Q33591729-81EBB0CF-445A-4DA3-93F5-36A0D0CC5D16Q33643203-90315B86-E583-430C-9485-AC6456840255Q33722378-3AAD44BD-0290-4C89-BAAC-621253F1DB61Q33734872-76106E17-9DA9-4E02-A357-C4338509765DQ33768267-7EE0A4B4-0025-4C82-A0A1-EE9118B024FFQ34205476-59465CB6-3488-4144-9017-477871358F68Q34813063-E62447F4-6B45-4210-ADE1-F769704CE62DQ35047669-6B10E2A9-311E-4E9B-AD8E-75C358151C55Q35553386-C133C7BB-6BEB-4185-AE7F-7E867F3A6259Q35558815-930BC9C8-B877-4997-B790-4DFD8BCECAA8Q35613340-C9916903-6498-4F90-A99F-CE7D888788D8Q35732096-8C0974CA-BBE9-4149-8702-877210E0BCC7Q35746388-C09B1101-8392-4990-AD75-F9CF66977D45Q35767479-3130F8B5-2DF2-45EC-938B-695246F7282FQ35922928-DA51A39A-CAD7-4420-A3C3-7CE293F75E6BQ35975542-271FE8D8-F200-46A0-8CB2-35D035D97DA7Q36216553-58D21923-69B4-426B-B019-2BF307155E29Q36306393-79142974-91DA-43D1-A4EB-ACF5E3CB442CQ36395715-0B33CA1B-7DF3-447B-A758-D8EC092AF60AQ36433529-3897E0AF-99F7-4EAB-9785-71D6BC7A3876Q36440010-92048065-C09D-47C5-8A94-AAA65780B781Q36560134-F8398392-5A41-4499-8BA7-C51ACDCF784AQ36611167-EBF43CCD-F057-46E6-A129-3DD46D7605F6Q36826198-604C0278-D8FC-4468-8EFE-700271A34E36Q36871982-07A947B0-9755-4AD4-B458-C023D1F42E99Q36920445-D2BB848E-C3DE-4C02-A7A7-06B95975A965Q37022512-49D0A5FA-6EA3-47AB-BFCE-544301334C22Q37050965-7B609D53-A236-4D67-84B1-7C04A8256046Q37074285-3D1D084C-C57B-475E-80BD-CE9509B282EBQ37179131-8CB69AE8-5568-4690-9643-61A1E37E818AQ37190393-B428DC78-E176-4AF9-A149-D659F7638F3C
P2860
High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
High risk of death due to bact ...... ects of primary CMV infection.
@en
High risk of death due to bacterial and fungal infection among cytomegalovirus
@nl
type
label
High risk of death due to bact ...... ects of primary CMV infection.
@en
High risk of death due to bacterial and fungal infection among cytomegalovirus
@nl
prefLabel
High risk of death due to bact ...... ects of primary CMV infection.
@en
High risk of death due to bacterial and fungal infection among cytomegalovirus
@nl
P2093
P356
P1476
High risk of death due to bact ...... ects of primary CMV infection.
@en
P2093
Chris Davis
Ted Gooley
W Garrett Nichols
P304
P356
10.1086/338624
P407
P577
2002-01-17T00:00:00Z